Radiopharmaceutical provider IBA Molecular has found a buyer for a Canadian PET radiopharmacy.
The sale was prompted by IBA's decision to form IBA Molecular through a joint venture deal with SK Capital Partners. For legal reasons, IBA Molecular operations in Canada could not be included in the new venture.
In its place, IBA has signed a letter of intent to sell its shares in Pharmalogic PET Services of Montreal for approximately $13.9 million U.S. (10.9 million euros) to a Canadian private equity firm.
The transaction could close within the next 60 days and result in a profit of approximately $11.2 million U.S. (9 million euros) for IBA.
